Evidence map›Paper›PMID 39738832›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

Targeted delivery of chrysin and 5-fluorouracil on MDA-MB-231 cancer cells by a peptide-functionalized L-DOPA-imprinted polymer.

Sedighe Yosefi, Majid Sirati-Sabet, Abbas Pakdel, Zahra Nabizadeh, Parviz Kokhaei, Hamid Madanchi

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sedighe YosefiDepartment of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Majid Sirati-SabetDepartment of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. sirati@sbmu.ac.ir.ORCID 0000-0002-8163-7075
Abbas PakdelNervous System Stem Cells Research Center, Semnan University of Medical Sciences, Semnan, Iran. pakdel@semums.ac.ir.ORCID 0000-0002-7173-367X
Zahra NabizadehCellular and Molecular Research Center, Qom University of Medical Sciences, Qom, Iran.
Parviz KokhaeiDepartment of Immunology, School of Medicine, Arak University of Medical Sciences, Arak, Iran.
Hamid MadanchiNervous System Stem Cells Research Center, Semnan University of Medical Sciences, Semnan, Iran. hamidmadanchi@yahoo.com.ORCID 0000-0002-6527-7321

Funding

Shahid Beheshti University of Medical Sciences IR.SBMU.MSP.REC.1401.245
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is a very aggressive and deadly form of breast cancer for which chemotherapy is the only systemic treatment option. Therefore, novel and more effective targeted or combined therapies, such as specific drug delivery systems that selectively target cancer cells, have received much attention. This research aimed to investigate the effect of targeted delivery of chrysin (CH) and 5-fluorouracil (5FU) using polymer nanoparticles on MDA-MB-231 cells. In this regard, CH and 5FU were individually used as the template to polymerize L-DOPA on the surface of silica nanoparticles. Then, a CD138-targeting peptide was designed for the first time and immobilized on the surface of the polymeric nanocomposite to target TNBC. The results showed that poly(L-DOPA)-CH-peptide and poly(L-DOPA)-5FU-peptide are selective for MDA-MB-231 cells and deliver drugs to them in a targeted manner. In this study, peptide-containing nanocomposites targeting CD138 were more successful in reducing cell proliferation than peptide-free nanocomposites. Also, they increased apoptosis and cell cycle arrest in MDA-MB-231 cancer cells in vitro. The effective and targeted delivery of CH and 5FU to MDA-MB-231 cancer cells by the designed interference peptide in this study can promise an effective treatment method for inhibiting the growth and progression of cancer. However, animal studies are needed to understand the efficacy of the interfering peptide and the final designed construct.

Indexed as

Antimetabolites, AntineoplasticFlavonoidsFluorouracilNanocompositesNanoparticle Drug Delivery SystemSyndecan-1Triple Negative Breast NeoplasmsHumansLevodopaMolecular Docking SimulationAntimetabolites, AntineoplasticchrysinFlavonoidsFluorouracilLevodopaNanoparticle Drug Delivery SystemSDC1 protein, humanSyndecan-1l-DOPAMolecular-imprinted polymersNanocompositeTumor-targeting peptide

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.